The IMID Forum
Avsnitt

Discussing axSpA: 52-week results from the Phase 3 BE MOBILE trials

The IMID Forum
Dela

Join Dr Sofia Ramiro and Dr Atul Deodhar as they discuss the top publications in the world of axSpA. This month, the conversation covered whether men and women with axSpA respond differently to bimekizumab, using 52-week data from the BE MOBILE 1 and 2 trials, covering both non-radiographic and radiographic axSpA.

Rss Apple Podcaster
Podden och tillhörande omslagsbild på den här sidan tillhör The Immune-Mediated Inflammatory Disease Forum. Innehållet i podden är skapat av The Immune-Mediated Inflammatory Disease Forum och inte av, eller tillsammans med, Poddtoppen.